

Jason Gotlib

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1558689/jason-gotlib-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169
papers

7,720
citations

37
h-index

87
g-index

231
ext. papers

9,335
ext. citations

6.4
avg, IF

6.14
L-index

#	Paper	IF	Citations
169	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101849	2.2	1
168	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	1
167	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021 ,	50.5	11
166	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , 2021 ,	50.5	10
165	Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. <i>Blood</i> , 2021 , 138, 2565-2565	2.2	0
164	A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). <i>Blood</i> , 2021 , 138, 3636-3636	2.2	1
163	Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. <i>Blood</i> , 2021 , 138, 318-318	2.2	1
162	Platelet Transcriptome Yields Progressive Markers in Chronic Myeloproliferative Neoplasms and Identifies Putative Targets of Therapy. <i>Blood</i> , 2021 , 138, 1469-1469	2.2	
161	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , 2021 , 5, e646	0.3	16
160	Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. <i>Cell Reports Medicine</i> , 2021 , 2, 100425	18	2
159	Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	5
158	Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
157	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1705-1712.e4	5.4	3
156	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021 , 5, 2481-2489	7.8	5
155	Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1719-1727	4.3	4
154	Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. <i>Blood Reviews</i> , 2021 , 45, 100693	11.1	1
153	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 487-498	5.4	4

152	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e19-e25	2.5	2
151	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021 , 11, 292-303	12.1	9
150	Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all "non-adverse-risk" AML. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1510-1513	1.9	1
149	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021 , 398, 803-816	4.0	17
148	Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF). <i>Leukemia Research</i> , 2021 , 108, 106606	2.7	3
147	Chronic Eosinophilic Leukemia: Diagnosis and Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S27-S29	2	
146	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2021 ,	10.7	5
145	World Health Organization-defined eosinophilic disorders: 2021 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2021 ,	7.1	10
144	Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. <i>Blood Advances</i> , 2021 , 5, 3492-3496	7.8	2
143	Myeloid/Lymphoid Neoplasms with Eosinophilia and TKI Fusion Genes: Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S66-S68	2	0
142	A novel activating JAK1 mutation in chronic eosinophilic leukemia. <i>Blood Advances</i> , 2021 , 5, 3581-3586	7.8	2
141	Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2700-2707	1.9	10
140	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 356-366.e4	11.5	15
139	Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 697-703.e1	2	4
138	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 1927-1938	9.3	15
137	New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. <i>Blood</i> , 2020 , 135, 1365-1376	2.2	45
136	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
135	Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All "Non-Adverse" Risk AML. <i>Blood</i> , 2020 , 136, 36-37	2.2	0

134	Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. <i>Blood</i> , 2020 , 136, 37-38	2.2	5
133	Sustained Complete Molecular Remission With Imatinib Monotherapy in a Child Presenting With Blast Phase -Associated Myeloid Neoplasm With Eosinophilia. <i>HemaSphere</i> , 2020 , 4, e486	0.3	0
132	Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1248-1269	7.3	10
131	Tyrosine Kinase Inhibitors in Systemic Mastocytosis 2020 , 257-265		
130	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020 , 95, E1-E3	7.1	3
129	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1075-1083	1.9	5
128	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020 , 34, 1090-1101	10.7	12
127	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020 , 10, 10743-10768	12.1	40
126	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2846-2856	2.2	41
125	Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. <i>Hematological Oncology</i> , 2019 , 37, 240-252	1.3	5
124	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1125-1133.e1	5.4	106
123	World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2019 , 94, 1149-1167	7.1	86
122	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019 , 6, e638-e649	14.6	42
121	Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor-Naïve Myelofibrosis Patients Treated with Momelotinib Compared Head to Head with Ruxolitinib. <i>Blood</i> , 2019 , 134, 1663-1663	2.2	3
120	Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. <i>Blood</i> , 2019 , 134, 2950-2950	2.2	2
119	Clinical Utility of a Multi-Gene Next-Generation Sequencing Myeloid Panel in an Academic Hematology Practice. <i>Blood</i> , 2019 , 134, 1408-1408	2.2	
118	A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis. <i>Blood Advances</i> , 2019 , 3, 2264-2271	7.8	8
117	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 81-87	5.4	24

116	Myelophthistic marrow involved by breast cancer and acute myeloid leukemia. <i>Blood</i> , 2018 , 131, 1036	2.2	
115	Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes 2018 , 1151-1169		
114	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). <i>Cancer Medicine</i> , 2018 , 7, 4447-4455	4.8	13
113	SOHO State-of-the-Art Update and Next Questions: MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 1-12	2	4
112	Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis. <i>Current Hematologic Malignancy Reports</i> , 2018 , 13, 407-416	4.4	11
111	Variability of PD-L1 expression in mastocytosis. <i>Blood Advances</i> , 2018 , 2, 189-199	7.8	5
110	The new tool "" in advanced systemic mastocytosis. <i>Hematology American Society of Hematology Education Program</i> , 2018 , 2018, 127-136	3.1	14
109	Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. <i>Blood Advances</i> , 2018 , 2, 1580-1584	7.8	14
108	A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. <i>International Journal of Hematology</i> , 2018 , 108, 267-273	2.3	1
107	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017 , 77, 1261-1270	10.1	162
106	Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017 , 92, E66-E68	7.1	8
105	Myeloid neoplasms with eosinophilia. <i>Blood</i> , 2017 , 129, 704-714	2.2	143
104	How I treat atypical chronic myeloid leukemia. <i>Blood</i> , 2017 , 129, 838-845	2.2	40
103	World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1243-1259	7.1	111
102	A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. <i>Cancer Genetics</i> , 2017 , 216-217, 10-15	2.3	10
101	Intricate and Cell Type-Specific Populations of Endogenous Circular DNA (eccDNA) in and. <i>G3: Genes, Genomes, Genetics</i> , 2017 , 7, 3295-3303	3.2	47
100	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017 , 26, 17-24	8.8	17
99	Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis. <i>Hematology/Oncology Clinics of North America</i> , 2017 , 31, 643-661	3.1	15

98	Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 432-441	4.4	13
97	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. <i>Clinical Cancer Research</i> , 2016 , 22, 757-64	12.9	32
96	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016 , 374, 2530-41	59.2	269
95	A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016 , 173, 253-9	4.5	2
94	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 35-45	11.5	209
93	Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016 , 57, 609-15	1.9	19
92	Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts. <i>Blood</i> , 2016 , 128, LBA-5-LBA-5	2.2	27
91	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1505-1512	7.3	44
90	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1348-1356	4.7	51
89	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016 , 101, 1133-1143	6.6	46
88	Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis. <i>Current Hematologic Malignancy Reports</i> , 2015 , 10, 351-61	4.4	8
87	Mutations in G protein βsubunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015 , 21, 71-5	50.5	60
86	World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2015 , 90, 1077-89	7.1	81
85	Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 424-34	7.3	18
84	A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients. <i>Blood</i> , 2015 , 126, 4092-4092	2.2	2
83	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015 , 126, 56-56	2.2	27
82	Mutation of the Calreticulin (CALR) Gene in Myeloproliferative Neoplasms 2015 , 12,		2
81	A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis. <i>Blood</i> , 2015 , 126, 2810-2810	2.2	

80	World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014 , 89, 325-37	7.1	95
79	Hereditary erythrocytosis, thrombocytosis and neutrophilia. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 95-106	4.2	17
78	Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1274-81	4.7	16
77	Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2014 , 38, 1441-5	2.7	9
76	Eosinophilic Myeloproliferative Disorders 2014 , 167-175		
75	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). <i>Blood</i> , 2014 , 124, 1826-1826	2.2	2
74	GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition. <i>Blood</i> , 2014 , 124, 3567-3567	2.2	3
73	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014 , 124, 636-636	2.2	12
72	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. <i>Blood</i> , 2013 , 122, 1707-11	2.2	128
71	Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. <i>New England Journal of Medicine</i> , 2013 , 368, 1781-90	59.2	388
70	Myeloid and lymphoid neoplasms with FGFR1 abnormalities: diagnostic and therapeutic challenges. <i>American Journal of Hematology</i> , 2013 , 88, 427-30	7.1	11
69	Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. <i>Haematologica</i> , 2013 , 98, 1689-96	6.6	9
68	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 121, 2393-401	2.2	89
67	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013 , 122, 106-106	2.2	6
66	Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis. <i>Blood</i> , 2013 , 122, 108-108	2.2	30
65	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. <i>Blood</i> , 2013 , 122, 2823-2823	2.2	4
64	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. <i>Blood</i> , 2013 , 122, 396-396	2.2	18
63	PI3K Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy. <i>Blood</i> , 2013 , 122, 4065-4065	2.2	1

62	Change In Albumin Levels During Induction Predicts Survival Outcomes In Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 1403-1403	2.2	
61	The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization. <i>Blood</i> , 2013 , 122, 270-270	2.2	
60	The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 2510-2510	2.2	
59	A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 799-807	59.2	1377
58	Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 607-612.e9	11.5	430
57	ICON: Eosinophil Disorders. <i>World Allergy Organization Journal</i> , 2012 , 5, 174-81	5.2	20
56	World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 903-14	7.1	37
55	Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. <i>Expert Review of Hematology</i> , 2012 , 5, 157-76	2.8	108
54	Estimation of JAK2 V617F Prevalence by Detection of the Mutation in Saliva Samples From Online MPN and General Population Cohorts. <i>Blood</i> , 2012 , 120, 1737-1737	2.2	2
53	A Germline Variant in the TERT Gene Is a Novel Predisposition Allele Associated with Myeloproliferative Neoplasms. <i>Blood</i> , 2012 , 120, 707-707	2.2	1
52	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012 , 120, 799-799	2.2	15
51	A Truncation Mutant of CSF3R, Identified As a Novel Driver in De Novo Myeloid Leukemia, Signals Through TNK2, and Is Responsive to Dasatinib.. <i>Blood</i> , 2012 , 120, 2412-2412	2.2	
50	Whole Genome Sequence Analysis of Primary Myelofibrosis.. <i>Blood</i> , 2012 , 120, 2863-2863	2.2	
49	Azacitidine Plus Lenalidomide for Untreated AML Patients Ineligible for Conventional Chemotherapy. <i>Blood</i> , 2012 , 120, 3575-3575	2.2	
48	FDA-Approved Ruxolitinib in Patients with Myelofibrosis: the Stanford Experience. <i>Blood</i> , 2012 , 120, 1747-1747	2.2	1
47	Correlation of Symptom Assessment with Genotyping Analysis of Saliva Samples in a Large Cohort of Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2012 , 120, 1732-1732	2.2	
46	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011 , 118, 1885-98	2.2	60
45	A novel splice donor mutation in the thrombopoietin gene leads to exon 2 skipping in a Filipino family with hereditary thrombocythemia. <i>Blood</i> , 2011 , 118, 6988-90	2.2	11

44	World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011 , 86, 677-88	7.1	53
43	BCL2 Splice Isoform Switching Promotes Leukemia Stem Cell Survival and Sensitivity to a Novel Pan BCL2 Inhibitor. <i>Blood</i> , 2011 , 118, 2735-2735	2.2	1
42	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. <i>Blood</i> , 2011 , 118, 278-278	2.2	8
41	Cycling Toward Leukemia Stem Cell Elimination With a Selective Sonic Hedgehog Antagonist. <i>Blood</i> , 2011 , 118, 3776-3776	2.2	4
40	Hydroxyurea [®] Leukemogenicity in Myeloproliferative Neoplasms: A Not Guilty Verdict 2011 , 8,		1
39	Eosinophilic Disorders: Differential Diagnosis and Management 2011 , 181-203		
38	Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. <i>Mayo Clinic Proceedings</i> , 2010 , 85, 158-64	6.4	118
37	JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. <i>Expert Review of Hematology</i> , 2010 , 3, 323-37	2.8	65
36	Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. <i>Current Opinion in Hematology</i> , 2010 , 17, 117-24	3.3	22
35	Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. <i>American Journal of Hematology</i> , 2010 , 85, 600-6	7.1	42
34	Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia. <i>Blood</i> , 2010 , 116, 3086-3086	2.2	1
33	KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. <i>Blood</i> , 2010 , 116, 316-316	2.2	25
32	The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010 , 116, 4742-4742	2.2	1
31	Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders. <i>Blood</i> , 2010 , 116, 315-315	2.2	2
30	A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, 3288-3288	2.2	
29	Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation StatusBased Treatment Stratification. <i>Blood</i> , 2010 , 116, 3313-3313	2.2	
28	A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2009 , 84, 15-20	7.1	33
27	When yellow jackets attack: recurrent and severe anaphylactic reactions to insect bites and stings. <i>American Journal of Hematology</i> , 2009 , 84, 843-6	7.1	4

26 Chronic Eosinophilic Leukemia/ Hypereosinophilic Syndrome **2008**, 69-106

25 Antiangiogenic therapy in myelodysplastic syndromes: is there a role?. *Current Hematologic Malignancy Reports*, **2008**, 3, 10-8 4.4 2

24 A Phase I Study of TG101348, An Orally Bioavailable JAK2-Selective Inhibitor, in Patients with Myelofibrosis. *Blood*, **2008**, 112, 97-97 2.2 12

23 The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.. *Blood*, **2007**, 110, 3536-3536^{2.2} 6

22 Missplicing of Glycogen Synthase Kinase 3 β A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.. *Blood*, **2007**, 110, 775-775 2.2 4

21 Hypereosinophilic Syndrome **2007**, 235-251

20 Dameshek Smiles: Molecular Clues to the Chronic Myeloproliferative Disorders Unmasked **2007**, 385-398

19 Large Granular Lymphocyte Leukemia: Clonality Reconsidered.. *Blood*, **2007**, 110, 3102-3102 2.2

18 KIT mutations in mastocytosis and their potential as therapeutic targets. *Immunology and Allergy Clinics of North America*, **2006**, 26, 575-92 3.3 38

17 Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. *Best Practice and Research in Clinical Haematology*, **2006**, 19, 535-69 4.2 48

16 Phase II Trial of the Tyrosine Kinase Inhibitor PKC412 in Advanced Systemic Mastocytosis: Preliminary Results.. *Blood*, **2006**, 108, 3609-3609 2.2 2

15 Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.. *Blood*, **2006**, 108, 3616-3616 2.2 2

14 Gene Expression Profile of Idiopathic Thrombocytopenic Purpura (ITP) Reveals Elevated Expression of Interferon Regulated Genes.. *Blood*, **2006**, 108, 702-702 2.2

13 Aberrant Regulation of Wnt/Beta-Catenin Pathway Mediators in Chronic Myelogenous Leukemia Stem Cells.. *Blood*, **2006**, 108, 2135-2135 2.2 0

12 Inhibition of Chronic Myelogenous Leukemia Stem Cells with Novel Wnt Antagonists.. *Blood*, **2006**, 108, 238-238 2.2 1

11 Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. *Blood*, **2005**, 106, 2865-70 2.2 211

10 Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. *Acta Haematologica*, **2005**, 114, 7-25 2.7 73

9 The Platelet-Derived Growth Factor Receptor beta Fuses to Two Distinct Loci at 3p21 in Imatinib Responsive Chronic Eosinophilic Leukemia.. *Blood*, **2005**, 106, 3253-3253 2.2 2

8	Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias.. <i>Blood</i> , 2005 , 106, 3260-3260	2.2	
7	Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment.. <i>Blood</i> , 2005 , 106, 696-696	2.2	0
6	Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. <i>Psychophysiology</i> , 2005 , 4, 77-84		16
5	The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. <i>Blood</i> , 2004 , 103, 2879-91	2.3	232
4	Tipifarnib (ZARNESTRA TM) in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.. <i>Blood</i> , 2004 , 104, 874-874	2.2	18
3	A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. <i>New England Journal of Medicine</i> , 2003 , 348, 1201-14	59.2	1426
2	Novel biospecific agents for the treatment of myelodysplastic syndromes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2003 , 1, 473-80	7.3	1
1	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR β -induced myeloproliferative disease. <i>Cancer Cell</i> , 2003 , 3, 459-69	24.3	208